The novel anti-androgen candidate galeterone targets deubiquitinating enzymes, USP12 and USP46, to control prostate cancer growth and survival

Por McClurg, Urszula L., Azizyan, Mahsa, Dransfield, Daniel T., Namdev, Nivedita, Chit, Nay C.T.H., Nakjang, Sirintra, Robson, Craig N.
Publicado no Oncotarget (2018)